High <i>Helicobacter pylori</i> Resistance to Metronidazole and Clarithromycin in Brazilian Children and Adolescents

Ogata, Silvio Kazuo; Godoy, Anita Paula Ortiz de; Patrı́cio, Francy Reis da Silva; Kawakami, Elisabete

doi:10.1097/mpg.0b013e31828b3669

Cited by 46 publications

(53 citation statements)

References 40 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In some countries, antimicrobial resistance has evolved with the use of antibacterial agents3,16). Table 1 shows recent the rates of H. pylori resistance to antimicrobials that are commonly administered to children in 10 countries17,18,19,20,21,22,23,24,25,26,27). The E-test has been established as a reliable modality for measuring antibiotic resistance to all antimicrobials, except for metronidazole for which it overestimates resistance.…”

Section: Antimicrobial Resistance Of H Pylori In Childrenmentioning

confidence: 99%

Antibiotics resistance ofHelicobacter pyloriand treatment modalities in children withH. pyloriinfection

et al. 2014

View full text Add to dashboard Cite

Pediatric infection with Helicobacter pylori may occur early in childhood and persist lifelong. Global pediatric clinical studies have reported a decreasing tendency in the overall rate of H. pylori eradication. In pediatric patients with H. pylori infection, pediatric patients with peptic ulcer, and the first-degree relatives of patients with a history of gastric cancer, it is commonly recommended that H. pylori strains be eradicated. Antibiotic drug resistance to H. pylori, which has been reported to vary widely between geographic regions, is mainly associated with treatment failure in these patients. It is therefore imperative that the antibiotic resistance rates of H. pylori in children and adolescents be meticulously monitored across countries and throughout geographic regions. This paper particularly focuses on the antibiotic drug resistance of H. pylori and the thearpy of pediatric H. pylori infection cases.

show abstract

Section: Antimicrobial Resistance Of H Pylori In Childrenmentioning

confidence: 99%

Antibiotics resistance ofHelicobacter pyloriand treatment modalities in children withH. pyloriinfection

et al. 2014

View full text Add to dashboard Cite

show abstract

“…All of tested H. pylori strains were susceptible to furazolidone and tetracycline. They conclude that the high resistance rate to metronidazole and clarithromycin could exclude them to empirical eradication treatment and otherwise there is no resistance to furazolidone and tetracycline, so we need to think about risks and benefits of using these drugs [8].…”

Section: Introductionmentioning

confidence: 99%

“…This drug present low bacterial resistance and it is effective against the strains of H. pylori and have a reduced cost [2,[7][8][9]. In 2002, Eisig et al [7] proposed a 7-day treatment based on furazolidone and tetracycline combined to a pump inhibitor (Omeprazole) in patients that had been previously treated.…”

Section: Introductionmentioning

confidence: 99%

Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?

Rizzuto¹,

Pasqualucci²,

Chehter³

2014

GHOA

View full text Add to dashboard Cite

a. Past or present duodenal and/or gastric ulcer, with or without complications. b. Following resection of gastric cancer. AbstractObjective: To analyze eradication rate and evaluate collateral effects of an existing alternative dosage, comprised of Omeprazole, tetracycline and furazolidone for 7 days in patients with gastric and/or duodenal ulcers and first-degree relatives of family members with a diagnosis of gastric cancer with positive study for Helicobacter pylori (H. pylori) and treatment-naive. Design and location:The out patients from the Clinic of the Gastroenterology Department of the ABC Medical School, Santo Andre, SP-Brazil. Results: 85 patients were included in the study of which 55 completed the treatment. 95% of the patients had an adequate adherence to the treatment. 49% of the patients analyzed by protocol had at least one side effect, with the most common being nausea (24%) and there was no statistical difference between the relation of side effects and lapse of treatment for H. pylori. 5% (3 patients) interrupted the treatment. The eradication rate per protocol (PP) was 96% (95%CI: 84% to 100%) for patients who completed the treatment. Patients and methods: Conclusion:The therapy based on Omeprazole, tetracycline and furazolidone in the dosages proposed represents a good and low-cost alternative to the first-line therapy to eradicate infection by H. pylori in treatment-naive patients in a developing country.

show abstract

“…Treatment of H. pylori infections consists of combination therapy involving two or three antibiotics, plus a proton pump inhibitor (2)(3)(4). However, the rate of unsuccessful eradication due to the emergence of antibiotic-resistant strains is growing (5,6). Furthermore, in regions with high rates of H. pylori infection, recurrent infection is more frequent (7).…”

Section: Introductionmentioning

confidence: 99%

The role of outer inflammatory protein A (OipA) in vaccination of theC57BL/6 mouse model infected by Helicobacter pylori

Mahboubi¹,

Falsafi²,

Sadeghizadeh³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

IntroductionStomach colonization by Helicobacter pylori is associated with gastritis, gastric ulcers, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma (1). Treatment of H. pylori infections consists of combination therapy involving two or three antibiotics, plus a proton pump inhibitor (2-4). However, the rate of unsuccessful eradication due to the emergence of antibiotic-resistant strains is growing (5,6). Furthermore, in regions with high rates of H. pylori infection, recurrent infection is more frequent (7). Hence, prevention would be an ideal strategy to resolve the problems associated with H. pylori infections, especially in regions with a high incidence of infection (8).Adherence to the gastric mucosa is the first step in successful colonization of the stomach by H. pylori, and among the bacterial factors essential for specific attachment to gastric epithelial cells, the outer membrane proteins (OMPs) play an important role (9). Background/aim: Outer inflammatory protein A (OipA) is an important adhesin of Helicobacter pylori. Our goal was to assess the role of OipA in protection of C57BL/6 mice against H. pylori.Materials and methods: C57BL/6 mice were mucosally immunized with recombinant OipA protein, OipA + propolis, propolis, and phosphate-buffered saline. After vaccination, anti-OipA IgA was measured. Mice were challenged three times with 5 × 10 7 CFU of the H. pylori B19 strain. Two weeks later, bacterial colonization and inflammation in the stomach was analyzed using standard methods. Results:The CFU number in the OipA group was significantly (P < 0.05) lower than that of the control. The CFU number in the OipA + propolis group was higher than those of the OipA and propolis groups. IgA titers were significantly higher (P < 0.0001) in the OipA group compared to the control and OipA + propolis groups. Propolis did not play an adjuvant effect but it interfered with the efficient vaccine effect of OipA. Conclusion:Results show the effect of vaccination by OipA in protection of the mouse model and the importance of OipA in H. pylori pathogenesis. OipA may be proposed as a suitable oral vaccine candidate against H. pylori infection; however, further study is required to determine adjuvant or adverse effects of propolis toward OipA.

show abstract

High Helicobacter pylori Resistance to Metronidazole and Clarithromycin in Brazilian Children and Adolescents

Cited by 46 publications

References 40 publications

Antibiotics resistance ofHelicobacter pyloriand treatment modalities in children withH. pyloriinfection

Antibiotics resistance ofHelicobacter pyloriand treatment modalities in children withH. pyloriinfection

Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?

The role of outer inflammatory protein A (OipA) in vaccination of theC57BL/6 mouse model infected by Helicobacter pylori

Contact Info

Product

Resources

About